MedCity News October 3, 2024
Frank Vinluan

Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE. The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026.

It’s getting more expensive to build labs and construction has fallen compared to peak activity during the pandemic. But there’s still plenty of lab space to go around, leaving building owners scrambling to try to fill it, according to findings in a new report this week from commercial real estate and investment firm CBRE.

The pandemic led to a boom in lab construction activity, feeding off of the surge of investments made in life science startups. Much but not all...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Survey / Study, Trends
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
Pharma Pulse 10/3/24: Data Collection Complexities, 8 Things You May Not Know About Breast Cancer & more
New Techniques Make RNA Accessible to Study Variants of Uncertain Significance
Comprehensive strategies for prescription drug cost management

Share This Article